News
OPK
1.380
+0.73%
0.010
Cautionary Tales On Why You Should Ignore Insider Buying
Seeking Alpha · 2d ago
Weekly Report: what happened at OPK last week (0928-1002)?
Weekly Report · 4d ago
OPKO Health (OPK) Sharpens Its Focus, Is It Still A Bargain?
Simply Wall St · 4d ago
Opko Health Triggers Conversion of 2029 Convertible Notes
TipRanks · 10/02 20:29
Weekly Report: what happened at OPK last week (0921-0925)?
Weekly Report · 09/28 10:18
How Investors May Respond To OPKO Health (OPK) Non Dilutive Financing
Simply Wall St · 09/23 14:33
Weekly Report: what happened at OPK last week (0914-0918)?
Weekly Report · 09/21 10:18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
Learn Why The Bull Case For OPKO Health (OPK) Could Change Following Royalty Backed Funding
Simply Wall St · 09/16 10:21
Safe Pro Group (NASDAQ: SPAI) Draws WhaleWatchAlerts Attention Following Phillip Frost’s $4M Share Purchase
TipRanks · 09/15 19:00
OPKO Health (OPK) Could Be 64% Undervalued On Its $125 Million Royalty Backed Financing
Simply Wall St · 09/14 17:23
Weekly Report: what happened at OPK last week (0907-0911)?
Weekly Report · 09/14 10:23
OPKO Health (OPK) Stock Looks Rich As Cash Flow Risks Cloud Fair Value
Simply Wall St · 09/10 20:19
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Barchart · 09/08 12:55
Weekly Report: what happened at OPK last week (0831-0904)?
Weekly Report · 09/07 10:17
Weekly Report: what happened at OPK last week (0824-0828)?
Weekly Report · 08/31 10:24
What OPKO Health (OPK)'s Royalty‑Backed, Capped‑Repayment Financing Deal Means For Shareholders
Simply Wall St · 08/27 00:37
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
NASDAQ · 08/24 15:15
Weekly Report: what happened at OPK last week (0817-0821)?
Weekly Report · 08/24 10:25
SA Asks: What are the most promising oncology companies right now?
Seeking Alpha · 08/22 21:57
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.